Shkreli predicted the stock would settle at approximately $2 per share, a significant drop from its current level. The stock ...

Shares of Capricor Therapeutics (CAPR) slumped 17% on Monday morning after former biotech executive and businessman Martin ...

Investing.com -- Capricor Therapeutics (NASDAQ:CAPR) stock plunged over 15% Monday after controversial former pharmaceutical executive Martin Shkreli identified the company as a short target.

Martin Shkreli has a penchant for being extraordinarily corny, and another one of his hare-brained schemes to be edgy landed him back in the clink. The Pharma Dweeb put out an offer to have someone ...

Martin Shkreli, former hedge fund manager known as Pharma Bro, scolded finance personalities for not understanding accounting ...

Once convicted of securities fraud, Shkreli now focuses primarily on stock trading. He shared a short position in Opendoor on X this week, drawing the ire of bullish retail investors. Martin Shkreli ...

Martin Shkreli guilty on three counts in securities fraud case A jury returned guilty verdicts Friday against Martin Shkreli, former CEO of Turing Pharmaceuticals, on one count of conspiracy to commit ...

NEW YORK (AP) — An unreleased Wu-Tang Clan album forfeited by Martin Shkreli after his securities fraud conviction was sold Tuesday for an undisclosed sum, though prosecutors say it was enough to ...

Former Turing Pharmaceutical CEO Martin Shkreli has started a bidding war on Twitter to win the chance to sock one to the industry’s notorious Pharma Boy, reports San Francisco Gate. Mr. Shkreli ...